Table 1   Clinical characteristic of the patient populations

	Oligo articular JIA		Poly articular JIA		Systemic JIA	
	plasma	SF	plasma	SF	plasma	SF
m/f	21/9	16/3	13/7	7/2	8/7	4/2
Age (years)	9.3 (3.0-15.1)	9.2 (2.1-17)	9.5 (2.1-14.8)	10 (3.6-17.1)	9.7(3.6-17.5)	9.6 (7.7-13.4)
Disease duration	5.9 (0.4-14.0)	4.7 (0.4-14.0)	4.7 (0.2-11.0)	4.4 (0.8-8.5)	2.7 (0.3-7.0)	5.9 (0.2-10.0)
Active/remission	20/10	19/0	13/7	9	8/7	6
ESR (mm/hr)	13.2 (2-55)	31.2 (7-104)	13.9 (5-47)	43.0 (7-80)	46.7 (5-171)	61.1 (1-171)
CRP (mg/L)	22.9 (<1-90)	34.1 (3-90)	29.5 (3-110)	35.2 (15-95)	45.0 (2-111)	33.0 (18-70)
ANA positive[1]	7 (23%)	13 (68%)	8 (40%)	2 (22%)	2 (22%)	0 (0%)
RF positve[2]	0 (05)	0 (0%)	3 (15%)	1 (11%)	0 (0%)	0 (0%)
NSAID	24 (80%)	18 (95%)	19 (95%)	8 (89%)	14 (93%)	6 (100%)
MTX	12 (40%)	8 (42%)	11 (55%)	7 (78%)	8 (53%)	5 (83%)
Corticosteroids	1 (3%)	1 (5%)	2 (10%)	2 (22%)	4 (27%)	4 (67%)
Anti TNFα	0 (0%)	0 (0%)	3 (15%)	1 (11%)	2 (13%)	2 (335)

ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, ANA = antinuclear antibody; RF = rheumatoid factor; NSAID = non steroid anti inflammatory drugs; MTX = methotrexate; 1 Determined by indirect immunofluorescence on Hep-2 cells; 2 Determined by IgM ELISA